Transplantation Flashcards

1
Q
# 1. Define allograft
2. Types of allograft
A
  1. Allograft: The transplant of an organ or tissue from one individual to another of the same species with a different genotype. For example, a transplant from one person to another, but not an identical twin, is an allograft.
  2. Types/examples:
  • Solid organs (kidney, liver, heart, lung, pancreas)
  • Small bowel
  • Free cells (bone marrow stem cells, pancreas islets)
  • Temporary: blood, skin (burns)
  • Privileged sites: cornea
  • Framework: bone, cartilage, tendons, nerves
  • Composite: hands, face
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the most common transplant performed?

A

Kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How can transplant outcomes be improved?

A
  • Improved surgical technique
  • Improved pre- and post-transplant patient management and monitoring

–Drug levels

–Infections, cardiovascular disease, diabetes,…

•Better understanding of transplant immunology

–>Better immunosuppressive agents

–> Prevention, diagnosis and treatment of graft rejection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 phases of the immune response to a transplanted graft?

A
  • Phase 1: recognition of foreign antigens
  • Phase 2: activation of antigen-specific lymphocytes
  • Phase 3: effector phase of graft rejection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the most relevant protein variations in clinical transplantation?

A
  • ABO blood group
  • HLA (human leukocyte antigens) coded in chromosome 6 by Major histocompatibility complex (MHC)

Other determinants - minor histocompatibility genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the two major components to rejection?

A

–T cell-mediated rejection

–Antibody-mediated rejection (B cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. What are HLA (Human leukocyte antigens)
  2. what do they do?
  3. What are their classes and variability?
A
  1. Cell surface proteins
  2. Presentation of foreign antigens on HLA molecules to T cells is central to T cell activation
  3. Classes:
  • HLA Class I (A,B,C)– expressed on all cells
  • HLA Class II (DR, DQ, DP) – expressed on antigen-presenting cells but also can be upregulated on other cells under stress
  • Highly polymorphic – hundreds of alleles for each locus (for example: A1, A2, A3 – A372 and rising…)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Why does everyone have a variety of HLA proteins?

A

To maximise diversity against infections

•The variability in HLA molecules in the population provides a source for immunisation against the transplanted organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the different MHC/HLA combinations

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the differences between MHC Class 1 and 2?

A

MHC Class 1: MHC class 1 are a class of major histocompatibility complex molecules found on the surface of all nucleated cells in mammals.

MHC Class 2: MHC class 2 are a class of major histocompatibility complex molecules mainly found on antigen presenting cells such as macrophages, dendritic cells, and B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When comparing HLA differences, what is the maximum amount of mismatches allowed across HLA-A, HLA-B and HLA-DR?

A

6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How many mismatches are in this example?

A

Remember HLA are proteins, so they come with two alleles, that may code for different versions of that HLA protein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is T cell mediated rejection?

A

T cells require presentation of the foreign HLA antigens by a professional antigen presenting cell (APC), in the context of HLA, to initiate activation of alloreactive T-cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the role of alloreactive T cells? Describe the direct and indirect pathways that lead to transplant rejection

A

T-cell alloreactivity drives transplant rejection. Alloreactive recognition is believed to proceed with limited specificity, accounting for the high numbers of alloreactive T cells in humans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the three signals that activate T cells after a transplant

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe how graft infiltration occurs with the help of cytotoxic T cells and macrophages

A

Graft infiltration by alloreactive CD4+ cells

“Cytotoxic” T cells

  • Release of toxins to kill target
    • Granzyme B
  • Punch holes in target cells
    • Perforin
  • Apoptotic cell death
    • Fas -Ligand

Macrophages

  • Phagocytosis
  • Release of proteolytic enzymes
  • Production of cytokines
  • Production of oxygen radicals and nitrogen radicals
17
Q

On a graft biopsy, what can be seen when acute cellular rejection has occurred?

A

Interstitial inflammation and tubulitis

18
Q

What are the 3 phases of antibody-mediated rejection?

A

Phase 1 – exposure to foreign antigen

Phase 2 - proliferation and maturation of B cells with antibody production

Phase 3 – effector phase; antibodies bind to graft endothelium (capillaries of glomerulus and around tubules, arterial)

19
Q

Describe the effectors in anti-body mediated rejection and whether they are naturally occuring or not

A

–Anti-A or anti-B antibodies are naturally occurring

–anti-HLA antibodies are not naturally occurring

  • Pre-formed – previous exposure to epitopes (previous transplantation, pregnancy, transfusion)
  • Post-formed - arise after transplantation
20
Q

Describe the action of antibodies in infection

A

B cells produce specific antibodies against the cell surface proteins on donor tissue, in an attempt to destroy it as it is considered a foreign article.

Complement is then activated allowing for cell adhesion, and attraction of other cells to cause cell necrosis to the cells of the donor tissue

21
Q

Describe how antibodies act to reject donor organs in transplant

A

B cells produce specific antibodies against the cell surface proteins on donor tissue, in an attempt to destroy it as it is considered a foreign article.

Complement is then activated allowing for cell adhesion, and attraction of other cells to cause cell necrosis to the cells of the donor tissue

22
Q

What makes the ABO blood groups?

A
  • A and B glycoproteins on red blood cells but also endothelial lining of blood vessels in transplanted organ
  • Naturally occurring anti-A and anti-B antibodies
23
Q

Describe what

  1. antibodies in plasma
  2. antigens on red blood cells

will be for blood groups A, B, AB and O

A
24
Q

Describe tissue rejection

A
  • T-cell mediated, antibody-mediated or combined
  • Both cause graft dysfunction (e.g. raised creatinine, raised LFT)
  • Graft biopsy: management and outcome are different
25
Q

Describe the prevention and treatment of graft rejection

A

•Preventing rejection:

  • A. AB/HLA matching
  • B. Screening for anti-HLA antibodies
  • C. Immunosuppression: dampen the immune system of the recipient

•Treating rejection:

  • More immunosuppression

•Always balance the need for immunosuppression with the risk of infection/malignancy/drug toxicity

26
Q
  1. Describe AB/HLA typing in transplantation
  2. When in HLA matching important in organ transplantation?
A

1.

  • Part of the organ allocation procedure
  • Encourage living donation from “blood” relatives

2.

•HLA matching is an important part of organ allocation procedure

  • Bone marrow
  • Kidney

•HLA matching not as important

  • Heart
  • Lung

•Liver - ?

27
Q

How is donor and receipient HLA type determined?

A

•PCR-based DNA sequence analysis determines the individuals genotype

28
Q

When should antibodies be screened for during transplantation proceedings?

A
  • Before transplantation
  • At time of transplantation: when a specific deceased donor kidney has been assigned to the patient
  • After transplantation, repeat measurements to check for new antibody production
29
Q

What 3 main types of assays are used to screen for anti-HLA antibodies?

A

–Cytotoxicity assays - does the recipient serum kill the donor’s lymphocytes in the presence of complement? – detection of cell death using vital dyes

–Flow cytometry - does the recipient’s serum bind to the donor’s lymphocytes (bound antibody detected by fluorescently-labelled anti-human Ig)

–Solid phase assays - does the recipient’s serum bind to recombinant single HLA molecules attached to a solid support such as beads (bound antibody detected by fluorescently-labelled anti-human Ig)

30
Q

How is transplant rejection managed?

A

More immunosuppression

  • Targeting T cell activation
    • Mycophenolate mofentil - affect nucleotide synthesis
    • Daclizumab - Anti-CD25 mAB
    • Alemtuzumab - Anti-CD52 mAB
    • Azathioprine - affects the cell cycle
    • Tacrolimus - Calcineurin inhibitors
  • Targeting antibody-mediated damage
    • Anti-CD20 antibodies
    • BAFF inhibitors
    • Proteasome inhibitors
    • Complement inhibitors
    • CD28/B7 blockade
    • Anti-CD40
31
Q

Describe some modern transplant immunosuppression

A
  • Induction agent ex. OKT3/ATG, anti-CD52, anti-CD25 (anti-IL2R)
  • Base-line immunosuppression: CNI inhibitor + MMF or Aza, with or without steroids
  • Treatment of episodes of acute rejection:
  • Cellular: steroids (MP IV 3x 60mg/kg then oral), ATG/OKT3
  • Antibody-mediated: IVIG, plasma exchange, anti-C5, anti-CD20
32
Q

What is haematopoietic stem cell transplants used for?

A
  • Haematological and lymphoid cancers
  • Acquired (autoimmune) or inherited deficiencies in marrow cells such as errors of metabolism or immunodeficiencies
33
Q

How does graft vs host disease occur in haemotopoietic stem cell transplants?

A
  • Eliminate hosts immune system (total body irradiation; cyclophophamide; other drugs)
  • Replace with own (autologous) or HLA-matched donor (allogeneic) bone marrow
  • Allogeneic HSCT leads to reaction of donor lymphocytes against host tissues
  • Related to degree of HLA-incompatibility
  • Also graft-versus-tumour effect
  • GVHD prophylaxis: Methotrexate/Cyclosporine
34
Q
  1. What is graft vs host disease?
  2. What happens?
  3. Treatments
A
  1. Injury induced by preparative regime before HSCT

2.

  • Skin: rash
  • Gut: nausea, vomiting, abdominal pain, diarrheoa, bloody stool
  • Liver: jaundice
  1. Treat with corticosteroids
35
Q

Describe post-transplantation infections

A

•Increased risk for conventional infections

–Bacterial, viral, fungal

•Opportunistic infections – normally relatively harmless infectious agents give severe infections because of immune compromise

–Cytomegalovirus

–BK virus

–Pneumocytis carinii

36
Q

Describe post transplantation malignancy

A

–Viral associated (x 100)

  • Kaposi’s sarcoma (HHV8)
  • Lymphoproliferative disease (EBV)

–Skin Cancer (x20)

–Risk of other cancers eg lung, colon also increased (x 2-3)